TrialScientific reports2024

Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US.

Junjie Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.